arrow
F

F. Facchetti

irccs ca granda ospedale maggiore policlinico
H指数:28
被引数:3,316

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mathematical modeling of HDV RNA, HBsAg, and ALT kinetics in patients with compensated cirrhosis: Insights from 96 Weeks of bulevirtide monotherapy

compensated肝硬变患者中HDV RNA、HBsAg和ALT动力学的数学建模:96周bulevirtide单药治疗的启示

2026-08-010
PRE
Fate of hepatitis D virus-specific CD8+ T cells during bulevirtide monotherapy in patients with chronic hepatitis delta☆
2026-07-240
OA
Dysregulated transcription in core- and pol-specific CD8 T cells can be targeted by HDAC inhibition to improve T-cell function in chronic hepatitis B

核心蛋白和聚合酶特异性CD8 T细胞中的失调转录可通过HDAC抑制来靶向,以改善慢性乙型肝炎中的T细胞功能

2026-06-060
PRE
ASAP score predicts early HCC recurrence after complete radiological response to locoregional treatments

ASAP评分可预测局部区域治疗后完全放射学缓解后的早期HCC复发

2026-01-030
PREAI
Comparison of diagnostic performances of HDV RNA quantification assays used in clinical practice: results from a national quality control multicenter study

临床实践中HDV RNA定量检测方法的诊断性能比较:一项国家质量控制多中心研究的结果

2025-08-060
OAAI
Rapid whole-blood immune profiling reveals heterogeneous HBV-specific T cell response patterns independent of clinical disease phases

快速全血免疫谱分析揭示了与临床疾病分期无关的异质性HBV特异性T细胞反应模式

2025-06-210
OAAI
HBsAg Isoforms as Innovative Biomarkers in Predicting Virological Response to Bulevirtide in Patients With Chronic Hepatitis D

乙型肝炎表面抗原异构体作为预测慢性丁型肝炎患者对布洛维替德病毒学应答的创新生物标志物

2025-04-280
PRE
Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV

比较接受布来韦尔替(bulevirtide)治疗与未治疗的丁型肝炎病毒(HDV)患者血浆中HDV RNA定量方法的比较

2025-03-010
OAAI
Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide

牛磺胆酸钠共转运多肽 (NTCP) 多态性可能会影响HDV RNA载量和对bulevirtide的早期反应

2024-11-012
PRE
Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations

在进入抑制剂bulevirtide下对HDV动力学进行建模表明存在两个HDV感染的细胞群

2024-02-012
OAAI
Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years

替诺福韦或恩替卡韦治疗11年的HBV代偿性肝硬化患者的长期内镜监测

2023-03-284
PRE
Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study

肝硬化患者新型冠状病毒肺炎mRNA疫苗接种后的刺突特异性体液和细胞免疫反应: 一项前瞻性单中心研究

2023-02-0116
OAAI
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension

Bulevirtide单药治疗HDV相关代偿性肝硬化和临床显着门脉高压患者48周

2022-12-0138
PRE